Asia-Pacific scleroderma therapeutics market is expected to grow at a CAGR of 4.4% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.
Market Segmentation
By Type (Localized Scleroderma, Systemic Scleroderma), Treatment Type (Drug Treatment, Surgical Treatment, Therapy), End User (Hospital, Specialty Clinics, Homecare Settings, Others), Country (Japan, China, Australia, South Korea, India, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2026

Major growing sectors under the market segmentation are as follows:

> In type, systemic scleroderma segment is dominating due to its awareness and treatment availability for its associated diseases. There are many products for this segment on which the clinical trials are going on.

> In treatment type, the drug treatment is growing segment as there are various drugs available in the market for the treatment of scleroderma related complications.

> In end user, hospital has a larger market than other end users because the treatment takes place majorly in hospitals.

Key Market Players

The key market players for Asia-Pacific scleroderma therapeutics market are listed below:

> Argentis Pharmaceuticals, LLC.
> F. Hoffmann-La Roche Ltd
> AbbVie Inc.
> Pfizer Inc.
> Sanofi
> ALLERGAN
> viDA Therapeutics Inc.
> Novartis AG
> Active Biotech AB.
> Bristol-Myers Squibb Company
> GlaxoSmithKline plc.
> Johnson & Johnson Services, Inc.
> AstraZeneca
> Daval International Limited
> Others